NCT01531179View on ClinicalTrials.gov

Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Necrotizing EnterocolitisVery Low Birth Weight Infants
Interventions
DRUG

Lactobacillus reuteri

Lactobacillus reuteri 100 million CFU/day for 3 months

DRUG

Placebo

Placebo for 3 months

Trial Locations (1)

06110

Zekai Tahir Burak Maternity Teaching Hospital, Neonatology Unit, Ankara

All Listed Sponsors
lead

Zekai Tahir Burak Women's Health Research and Education Hospital

OTHER

NCT01531179 - Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants | Biotech Hunter | Biotech Hunter